Skip to content

Ketamine for depression: all studies

Page 21 of 178: studies 201 to 210 of 1,775, newest first. Back to the ketamine for depression overview

Research

A novel sequential ketamine and D-cycloserine/lurasidone therapy for bipolar depression with acute suicidal ideation.

Expert Opinion on Investigational Drugs May 26, 2026 Mina Takahashi, Richard C. Shelton

INTRODUCTION: Bipolar depression with acute suicidal ideation and behavior (ASIB) is a life- threatening manifestation of bipolar disorder (BD), with a suicide risk higher than that in other psychiatric disorders and the general population. Rapid and effective interventions are critical, as traditional therapies are often slow and frequently insufficient. Currently, no drug is approved by the...

Pharmacotherapeutic Options in Drug-Resistant Bipolar Depression: From Molecular Mechanisms to Rational Polypharmacotherapy.

Biomedicines May 23, 2026 Dominik Jucha, Michał Klimas, Dominika Wiśniewska et al.

Background/Objectives: Bipolar disorder affects about 40 million people worldwide, and the greatest burden of the disease is associated with depressive episodes. About 25% of patients experience drug-resistant depression, in which standard treatment turns out to be insufficient, and monotherapy often does not bring full remission. Despite the use of second-generation antipsychotics, the...

Shorter to be effective: subanesthetic-dose ketamine infusion reduces the global and regional path length of brain functional connectivity in patients with treatment-resistant depression and suicidal ideation.

Psychopharmacology May 22, 2026 Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al.

Background: Studies have demonstrated that subanesthetic-dose ketamine may modulate the functioning of specific depression-related brain regions, particularly the anterior cingulate cortex and prefrontal cortex. However, how subanesthetic-dose ketamine alters the global and regional graph theory metrics of resting-state functional connectivity in patients with treatment-resistant depression...

Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.

Therapeutic Advances in Psychopharmacology May 22, 2026 Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.

Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI,...

Effect of ketamine intervention on hemodynamic responses in patients with treatment-resistant depression.

Scientific Reports May 20, 2026 Guan-Jie She, Wei-Chi Li, Chun-Hsiang Chou et al.

Emerging evidence shows that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, can produce rapid anti-suicidal effects in treatment-resistant depression, yet its underlying neuropharmacological mechanisms remain elusive. The present study aimed at investigating the therapeutic effect of ketamine infusion on suicidal ideation by examining hemodynamic response changes in resting-state...

Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis.

Pharmacological Reports May 20, 2026 Aleksander Kwaśny, Alina Wilkowska, Michał Pastuszak et al.

Background: Treatment-resistant depression (TRD) poses a significant therapeutic challenge, with remission often unattainable. Recognition and detection of treatment-emergent adverse events (TEAEs) are essential, as these events may significantly influence the quality of treatment response. This knowledge aids in personalizing care and selecting the best treatment strategy. Methods: In a...

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

Journal of Affective Disorders May 16, 2026 David S. Mathai, Madeleine Cluck, Amna M. Aslam et al. 1 citation

Background: Off-label use of intravenous ketamine (IVK) for depression is a widespread practice with limited regulation in the United States. There is an urgent need for current, evidence-informed treatment guidelines to facilitate patient safety, clinical decision-making, and care quality in real-world contexts. Methods: The American Society of Ketamine Physicians, Psychotherapists and...

Short-term effects of oral ketamine for the treatment of depression: A systematic review and meta-analysis of randomized controlled trials.

Asian Journal of Psychiatry May 16, 2026 Sonia Shenoy, Vijetha Shenoy Belle, Ravindra Neelakanthappa Munoli et al. 1 citation

Background: Oral ketamine is a novel treatment for management of depression. However, evidence related to its effectiveness and safety is unavailable. This systematic review aimed to assess the short-term efficacy and safety of oral ketamine compared to placebo or other modes of ketamine in randomized controlled trials (RCT) in unipolar depression, bipolar depression, and treatment-resistant...

DOI: 10.1016/j.ajp.2026.105014 (opens in new tab) Depression Humans Antidepressive agents Administration, oral +4

Toward Integrating Intranasal Esketamine with Traumatic-Memory Psychotherapy in Treatment-Resistant Depression: A Narrative Review and Feasibility-Oriented Protocol Proposal.

Behavioral Sciences May 14, 2026 Fabiola Raffone, Carlo Ignazio Cattaneo, Enrico Pessina et al.

Trauma-related autobiographical memories can manifest as involuntary, vivid, emotionally charged intrusions that perpetuate avoidance, negative emotions, and functional impairment. While these memories are central to post-traumatic stress disorder (PTSD), they also occur across diagnoses and are often reported in depressive disorders, including treatment-resistant depression (TRD). Although...